- A new hormone-free male contraceptive pill, YCT-529, has demonstrated safety in early-stage clinical trials.
- Developed by YourChoice Therapeutics, the drug works by blocking vitamin A metabolites to prevent sperm production without impacting sex hormones.
- The trial, involving 16 male volunteers, reported no adverse side effects, including on cardiac health, hormone levels, or mood.
- The innovation offers a potential alternative to existing male contraception.
- While hailed as an "exciting step forward", experts highlight the need for further testing to confirm the pill’s efficacy in preventing pregnancy and to address market costs.
IN FULL